FORT LAUDERDALE, Fla., Jan. 27 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS), a pioneer in laser optical breast imaging, will exhibit the CT Laser Mammography (CTLM(R)) system at the Arab Health 2009 medical conference, January 26-29, 2009, in Dubai, United Arab Emirates (UAE). The company will demonstrate the CTLM system at booth RQ18.
IDSI will select new distributors for the UAE and intends to secure prospective sales of the CTLM system based on leads from the RSNA 2008 conference.
"Arab Health is an important show for us, especially this year, as we will continue to build our distributor network in the middle east and for the first time demonstrate the CTLM system at the booth to those who may not be familiar with the modality," stated Deborah O'Brien/Senior Vice President of Imaging Diagnostic.
The Arab Health exhibition and congress is the region's premier event for the Middle East, bringing healthcare manufacturers, wholesalers, dealers and distributors together with some of the most important and influential decision-makers in the Arab world. With the market in the UAE becoming more competitive and buying cycles in both the public and private sectors increasing, Arab Health 2009 is an ideal opportunity for companies to display their latest technology and equipment. As one of the largest and most prestigious healthcare events in the Middle East, with over 3,000 exhibitors from over 65 countries and more than 60,000 medical professionals, it is recognized as the global show, and for many companies, the one event, to attend in the exhibition calendar year.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
The Company is currently collecting clinical data for the Pre-market approval application in hopes to gain FDA marketing clearance in the United States. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.
For more information, visit our website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
|SOURCE Imaging Diagnostic Systems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved